Avalo Therapeutics medical chief sells $20,000 in stock

Mittie Doyle, chief medical officer of Avalo Therapeutics, sold $20,000 worth of company stock on August 17, 2026, through a pre-arranged trading plan, while simultaneously exercising options to acquire additional shares. Doyle sold 1,000 shares at $20.00 each and exercised options to buy 1,000 shares at $12.65 each, totaling $12,650. The transactions occurred under a Rule 10b5-1 plan adopted in November 2025, leaving her with 51,776 direct shares and 123,750 options. The sale follows an 83% stock gain over the past year, with shares trading near their 52-week high. Avalo recently joined the Russell 2000 and 3000 indexes, appointed Ron Philip to its board, and received analyst support for its lead drug candidate abdakibart.